BioCentury | May 20, 2020
Deals

Roche deal, AACR data unveil Vividion’s targeted degradation strategy

...multiple tissues within four hours. Vividion generated compounds that induced degradation of the epigenetic regulator BRD4...
...it is going after E3 ubiquitin ligases, adaptor proteins and transcription factors. Targets BRD4 - Bromodomain containing 4...
BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

...testing the 69 compounds for antiviral activity. Repurposing candidates include at least two that inhibit BRD2/BRD4...
...crisis can be found at https://www.biocentury.com/coronavirus . Targets BRD2 - Bromodomain containing 2 BRD4 - Bromodomain containing 4...
BioCentury | Mar 21, 2020
Finance

Design debuts with $45M series A, portfolio against repeat expansions

...through the minor groove, Shah said. The other end works to unblock transcription by recruiting BRD4...
...by recruiting BRD4 to GAA repeats in the first intron of the FNX-gene; in turn, BRD4...
...repair pathway targets to prevent expansion (see "Triplet Debuts with $59M" ). Targets BRD4 - Bromodomain containing 4...
BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

...II for renal damage. Resverlogix Corp. (TSX:RVX) has apabetalone (RVX000222, RVX-208), which targets APOA1 and BRD4...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...27 patients (47%), 6 >12 weeks 3013 AstraZeneca (LSE:AZN; NYSE:AZN) AZD5153 Small molecule inhibitor of bromodomain containing 4 (BRD4)...
...Histone cluster 2 H2B family member F (HIST2H2BF) Solid tumors and lymphoma AZD5153 is a bromodomain containing 4 (BRD4)...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

...DS-3032 MDM2 p53 binding protein homolog (MDM2; HDM2) inhibitor Solid tumors, AML Ph I PLX2853 Bromodomain containing 4 (BRD4)...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

...INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting the BRD4-FOXO3-CDK6 axis could...
...those who remained disease-free. In three human luminal breast cancer cell lines, an siRNA targeting BRD4...
...have CK-103, a BRD4 inhibitor, in preclinical testing for hematologic malignancies and solid tumors. TARGET/MARKER/PATHWAY: Bromodomain containing 4 (BRD4)...
BioCentury | Dec 11, 2018
Distillery Therapeutics

Inflammation

...INDICATION: Inflammatory disease Cell culture studies suggest combined inhibition of BRD4 and HDAC could help treat...
...from patients deficient in the type I interferon regulators ISG15 or USP18, a tool compound BRD4...
...have CK-103, a BRD4 inhibitor, in preclinical testing for hematologic malignancies and solid tumors. TARGET/MARKER/PATHWAY: Bromodomain containing 4 (BRD4)...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...of mTORC1 pathway deficiency in AML ( No. 178 ), and inhibition of chromatin reader BRD4...
...a targeted degrader against the chromatin reader BRD4, induces sustained BRD4 depletion and down-regulation of BRD4...
...2 early onset BRD2 - Bromodomain containing 2 BRD3 - Bromodomain containing 3 BRD4 - Bromodomain containing 4...
BioCentury | Nov 6, 2018
Preclinical News

Foghorn co-founder shows chromatin remodeling inhibition could treat sarcoma

Dana-Farber Cancer Institute researchers, including Foghorn Therapeutics Inc. (Cambridge, Mass.) co-founder Cigall Kadoch, and colleagues suggested inhibitors of the chromatin remodeling non-canonical BAF complex (ncBAF) could help treat sarcomas. Three SWI/SNF complexes with distinct but...
Items per page:
1 - 10 of 156